Stealth Lipid Nanoparticles for Immune Cell-Targeted Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing CAR T-cell therapies for cancer treatment face challenges such as cytokine release syndrome and inefficient, unsafe delivery of therapeutic cargo to target cells, necessitating improved methods for in vivo and ex vivo delivery of nucleic acids to immune effector cells.
Innovation Solution
Development of stealth lipid nanoparticles (LNPs) that encapsulate therapeutic nucleic acids, comprising ionizable lipids, sterols, and lipid-anchored polymers with reactive moieties and targeting moieties, enhancing blood circulation time and specific cell targeting capabilities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional delivery methods are used for therapeutic cargo, then delivery can be achieved, but delivery efficiency is low and adverse reactions occur
Solution Approach 1:
The patent modifies the physical and chemical parameters of the delivery system by using ionizable lipids that change their properties at different pH levels. These lipids remain neutral in blood circulation (reducing immune recognition) but become positively charged in endosomes (enhancing cargo delivery), thereby improving delivery efficiency while reducing adverse reactions
Solution Approach 2:
The patent employs composite lipid nanoparticle formulations combining ionizable lipids with sterols and helper lipids. This composite structure provides both the stealth properties needed to avoid immune detection (reducing adverse reactions) and the endosomal escape capability needed for efficient cargo delivery (improving delivery efficiency)
2Manufacturing precision
If targeting capability is enhanced for specific cell types, then therapeutic precision improves, but circulation time may be reduced due to immune recognition
Solution Approach 1:
The patent pre-conjures targeting moieties (such as antibodies or peptides) to the LNP surface before administration. These targeting moieties are strategically positioned to recognize specific cell surface markers, enabling precise cell targeting while the PEGylated surface maintains circulation by preventing premature immune recognition
Solution Approach 2:
The patent applies different functional properties to different parts of the LNP structure: the surface is PEGylated for stealth and circulation, while specific localized regions contain targeting moieties for cell type specificity. This spatial differentiation allows the particle to simultaneously achieve long circulation time and high targeting precision
3Duration of action of moving object
If stealth properties are enhanced for prolonged circulation, then blood half-life increases, but targeting capability may be reduced due to surface coverage
Solution Approach 1:
The patent uses dynamic PEGylation strategies where PEG chains can be adjusted in length and density to optimize the balance between stealth properties and targeting capability. The PEG corona provides steric protection for circulation while allowing targeting moieties to remain accessible at the particle surface, achieving both prolonged half-life and maintained targeting capability
Data Source
AI summary
The present disclosure provides stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types, e.g., T cells, B cells, natural killer cells, to genetically modify the cells with therapeutic nucleic acid encapsulated in the LNP. The present disclosure also provides compositions and methods of making the LNPs and treatment using the same.